Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma 225Lymphoma, Large B-Cell, Diffuse 160Precursor Cell Lymphoblastic Leukemia-Lymphoma 143Lymphoma, Non-Hodgkin 139Hodgkin Disease 106Burkitt Lymphoma 99Lymphoma, Follicular 85Leukemia 82Lymphoma, Mantle-Cell 76Lymphoma, Large-Cell, Immunoblastic 68Leukemia, Lymphocytic, Chronic, B-Cell 56Lymphoma, B-Cell, Marginal Zone 43Leukemia, Myeloid, Acute 34Recurrence 31Lymphoma, B-Cell 31Lymphoma, Large-Cell, Anaplastic 30Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 29Dendritic Cell Sarcoma, Interdigitating 29Lymphoma, Extranodal NK-T-Cell 26Multiple Myeloma 24Waldenstrom Macroglobulinemia 22Myelodysplastic Syndromes 22Lymphoma, T-Cell, Peripheral 22Lymphoma, T-Cell, Cutaneous 20Blast Crisis 19Lymphoma, T-Cell 18Leukemia, Myeloid, Accelerated Phase 18Immunoblastic Lymphadenopathy 18Congenital Abnormalities 18Neoplasms, Plasma Cell 16

Interventions

Nivolumab 2prednylidene 1peginterferon alfa-2b 1dolutegravir 1deltacortene 1Zidovudine 1Vincristine 1Valproic Acid 1Tenofovir 1Specimen Handling 1Prednisone 1Pharmacogenomic Testing 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Interferon alpha-2 1Etoposide 1Doxorubicin 1Daclizumab 1Cyclophosphamide 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HTLV-I Infections × Etoposide × Lymphoid × Clear all
NCT04301076 2026-05-13

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡